A Phase II Study of Paclitaxel/Cisplatin Combination in Patients with Metastatic Breast Cancer Refractory to Anthracycline-Based Chemotherapy
The DOI matches its Crossref record; 14 of the 14 references it cites were found in a registry or an index.
Abstract
Aims and background: To investigate the safety and efficacy of a paclitaxel and cisplatin regimen in a selected group of metastatic breast cancer patients with primary or acquired chemoresistance to anthracycline-based chemotherapy. Patients and methods: Thirty-eight consecutive women with metastatic breast cancer (PS ≤2) were entered in this phase II trial; all patients had been previously treated for metastatic disease with chemotherapy containing anthracyclines and had shown a progression of the disease during drug administration or after a clinical response lasting less than 6 months. Fifteen patients had received 2 or more chemotherapeutic regimens for advanced disease; 31 patients had ≥2 sites of metastatic disease. Paclitaxel (135 mg/m 2 ) was administered iv by a 3-hr infusion followed by iv infusion of cisplatin (75 mg/m 2 ) on day 1, every 3 weeks for 6 cycles. After the completion of the planned chemotherapy administration, 9 responsive patients continued to receive paclitaxel alone (175 mg/m 2 ) iv, on day 1, every 3 weeks, until disease progression or unacceptable toxicity. Results: A partial clinical response was recorded in 17 cases (45%; 95% CI, 30–64%). The median duration of overall response was 8 months; for the 9 responsive patients who continued treatment with paclitaxel alone, 4 had maintained the partial clinical response at the median follow-up of 24 months from the onset of therapy. The median time to progression was 6 months and median overall survival 8 months. Neurotoxicity was the most frequent adverse effect and caused treatment discontinuation in 5 cases for grade 3–4 paresthesia and/or an arthralgia/myalgia syndrome. Grade 3–4 neutropenia occurred in 16 patients (44%). Conclusions: Paclitaxel/cisplatin is an active regimen for the treatment of patients with metastatic breast cancer refractory to anthracycline-based chemotherapy. However, the cumulative neurotoxicity should limit the efficacy of prolonged paclitaxel monotherapy in responsive patients.
Overview
Integrity signals
Registry
Cites
Statistics
Verification
Claims the paper makes
Claims other papers make about this one
Each is checked against this paper’s own text: does it say what the citing paper says it does?
In the citing paper
“As a result, the PTX/CP molar ratios varied from ~0.2 to ~1.9 PTX/C6CP or ~0.25 to ~2.25 for PTX/C10CP, and were close to PTX/cisplatin dose ratios used in the clinical chemotherapy regimens [18].”
In the citing paper
“When recalculated to the human equivalent dose (HED) based on the body surface area [24] these doses corresponded to ~60 mg/m2 (~1.6 mg/kg) for PTX and ~31–33 mg/m2 (~0.83–0.89 mg/kg) for cisplatin, which is approximately half of the doses used in clinic for the PTX (135 mg/m2) and cisplatin (75 mg/m2) combination [18].”
Citations
Cites
Nonparametric Estimation from Incomplete Observations
Kaplan, E. L., & Meier, P. (1958) · Journal of the American Statistical Association · doi:10.1080/01621459.1958.10501452 · Cited by 39,158
Reporting results of cancer treatment
Miller, A. B., Hoogstraten, B., Staquet, M., & Winkler, A. (1981) · Cancer · doi:10.1002/1097-0142(19810101)47:1<207::aid-cncr2820470134>3.0.co;2-6 · Cited by 7,793
Sequences of taxol and cisplatin: a phase I and pharmacologic study.
Rowinsky, E. K., Gilbert, M. R., McGuire, W. P., Noe, D. A., Grochow, L. B., Forastiere, A. A., Ettinger, D. S., Lubejko, B. G., Clark, B., & Sartorius, S. E. (1991) · Journal of Clinical Oncology · doi:10.1200/jco.1991.9.9.1692 · Cited by 426
Postma, T. J., Vermorken, J. B., Liefting, A. J. M., Pinedo, H. M., & Heimans, J. J. (1995) · Annals of Oncology · doi:10.1093/oxfordjournals.annonc.a059220 · Cited by 271
Synergistic interaction between cisplatin and taxol in human ovarian carcinoma cells in vitro
Jekunen, A., Christen, R., Shalinsky, D., & Howell, S. (1994) · British Journal of Cancer · doi:10.1038/bjc.1994.55 · Cited by 128
Webster, L. K., Linsenmeyer, M. E., Millward, M., Morton, C. G., Bishop, J. F., & Woodcock, D. M. (1993) · JNCI Journal of the National Cancer Institute · doi:10.1093/jnci/85.20.1685 · Cited by 128
Rowinsky, E. K., Citardi, M. J., Noe, D. A., & Donehower, R. C. (1993) · Journal of Cancer Research and Clinical Oncology · doi:10.1007/bf01195344 · Cited by 92
Wasserheit, C., Frazein, A., Oratz, R., Sorich, J., Downey, A., Hochster, H., Chachoua, A., Wernz, J., Zeleniuch-Jacquotte, A., Blum, R., et al. (1996) · Journal of Clinical Oncology · doi:10.1200/jco.1996.14.7.1993 · Cited by 88
Cisplatin and its analogues in the treatment of advanced breast cancer: a review
Smith, I., & Talbot, D. C. (1992) · British Journal of Cancer · doi:10.1038/bjc.1992.169 · Cited by 72
Phase I/II trial of biweekly paclitaxel and cisplatin in the treatment of metastatic breast cancer.
Gelmon, K. A., OʼReilly, S., Tolcher, A. W., Campbell, C., Bryce, C. J., Ragaz, J., Coppin, C., Plenderleith, I. H., Ayers, D., McDermott, B., et al. (1996) · Journal of Clinical Oncology · doi:10.1200/jco.1996.14.4.1185 · Cited by 59
Research works printed but not linked: 5
- Gianni L., 1994, Semin. Oncol., 21, 29
- Henderson I.C., 1987, Breast disease,, 428
- Horwitz S.B., 1993, J. Natl. Cancer Inst., 15, 15
- Perez T., 1995, Eur. J. Cancer, 31, 575
- Vermorken J.B., 1993, Eur. J. Cancer, 29, 435
Cited by
Cell cycle-mediated drug resistance: an emerging concept in cancer therapy.
Shah, M. A., & Schwartz, G. K. (2001) · PubMed · Cited by 518
Platinum-based chemotherapy in metastatic breast cancer: current status
Decatris, M. P., Sundar, S., & O’Byrne, K. J. (2004) · Cancer Treatment Reviews · doi:10.1016/s0305-7372(03)00139-7 · Cited by 211
Wan, X., Beaudoin, J. J., Vinod, N., Min, Y., Makita, N., Bludau, H., Jordan, R., Wang, A., Sokolsky, M., & Kabanov, A. V. (2019) · Biomaterials · doi:10.1016/j.biomaterials.2018.10.032 · Cited by 201
Platinum Compounds in the Treatment of Advanced Breast Cancer
Martín, M. (2001) · Clinical Breast Cancer · doi:10.3816/cbc.2001.n.022 · Cited by 79
Chemotherapy for metastatic breast cancer–report of a European expert panel
Crown, J. P., Dieras, V. C., Kaufmann, M., von Minckwitz, G., Kaye, S. B., Leonard, R. C., Marty, M. E., Misset, J. L., Osterwalder, B., & Piccart, M. J. (2002) · The Lancet Oncology · doi:10.1016/s1470-2045(02)00927-0 · Cited by 77
Metadata
- Authors
- Rosati, G., Riccardi, F., Tucci, A., De Rosa, P., & Pacilio, G.
- Affiliations
- Ospedale San Carlo (IT)
- Ospedale Antonio Cardarelli (IT)
- Division of Medical Oncology, “A. Cardarelli'’ Hospital, Naples, Italy
- Venue
- Tumori Journal
- Publisher
- SAGE Publications
- Published
- 2000-05
- Volume
- 86
- Issue
- 3
- Pages
- 207-210
- ISSN
- 0300-8916 (ISSN-L)
- 2038-2529
- OpenAlex
- W2409903753
- Cited by
- 17
- References
- 14
- Citations by year
- 2023: 2 · 2022: 2 · 2021: 1 · 2018: 3 · 2015: 1 · 2013: 1
- FWCI
- 0.59
- Type
- journal article
- Language
- en
- Open access
- closed
- Licence
- journals.sagepub.com/page/policies/text-and-data-mining-license (tdm)
- Locations
- Tumori Journal (publishedVersion)
- PubMed (publishedVersion)
- Topics
- Health Sciences › Medicine › Oncology › Cancer Treatment and Pharmacology
- Life Sciences › Biochemistry, Genetics and Molecular Biology › Cancer Research › Breast Cancer Treatment Studies
- Health Sciences › Medicine › Oncology › Advanced Breast Cancer Therapies
- Keywords
- metastatic breast cancer, paclitaxel, cisplatin, anthracycline resistance, combination chemotherapy, neurotoxicity, neutropenia, treatment response, overall survival
- MeSH terms
- Adult, Aged, Antibiotics, Antineoplastic, Antineoplastic Combined Chemotherapy Protocols, Antineoplastic Agents, Phytogenic, Breast Neoplasms, Cisplatin, Drug Administration Schedule, Female, Humans, Male, Middle Aged, Peripheral Nervous System Diseases, Survival Analysis, Treatment Outcome, Paclitaxel, Disease Progression, Drug Resistance, Neoplasm
About these checks
Registry, retraction, Cites and statistics results are computed, not judged, with one exception: a printed reference that no index lists is read once by a model before it counts as a citation error. Claims are extracted by a model and kept only when their quote appears verbatim in the text; each cited source is then checked, with a model’s help, for whether it says what the claim relies on. Those verdicts can be wrong — read the claim’s quote and the cited source before relying on one.
Statistics and arithmetic are recomputed, not judged.
Confidence bands are shown only for fields calibrated on our annotated test set. None is calibrated yet, so no band is shown.
What counts as a claim ›How we measure confidence ›How we check this ›
Are you an author, or do you see a problem with this page? Request a review
How to cite
Cite CoChat for the checks on this page, and the paper for its own findings.
- This page
- CoChat. (2026). Citation check: A Phase II Study of Paclitaxel/Cisplatin Combination in Patients with Metastatic Breast Cancer Refractory to Anthracycline-Based Chemotherapy. https://app.cochat.ai/papers/10.1177/030089160008600306
- The paper
- Rosati, G., Riccardi, F., Tucci, A., De Rosa, P., & Pacilio, G. (2000). A Phase II Study of Paclitaxel/Cisplatin Combination in Patients with Metastatic Breast Cancer Refractory to Anthracycline-Based Chemotherapy. Tumori Journal. https://doi.org/10.1177/030089160008600306
Data sources
Bibliographic data: Semantic Scholar, OpenAlex, Crossref.
Contains information from the Semantic Scholar Academic Graph Datasets, made available under the ODC Attribution License (ODC-BY 1.0).
Semantic Scholar’s data is described in: Kinney, R., et al. (2023). The Semantic Scholar Open Data Platform. arXiv:2301.10140.